Barchart.com
Less than $10/month! Screen on your Watchlists and Portfolios with Barchart Plus. FREE 30 Day Trial
Menu
alerts false
Stocks | Futures | Watchlist | News | More
 
Advanced search
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Menu

Casi Pharmaceuticals Inc (CASI)

Casi Pharmaceuticals Inc (CASI)
2.26 +0.04 (+1.57%) 03/17/25 [NASDAQ]
2.20 x 1,000 2.49 x 1,400
Realtime by (Cboe BZX)
2.20 x 1,000 2.49 x 1,400
Realtime - - (-) -
News & Headlines for Mon, Mar 17th, 2025
Notes
Alerts
Watch
    Add or delete the symbol from one or more Watchlists.
  • Create New Watchlist
    This name already in use.
Help
Go To:
CASI Announces First Patient Dosed in Phase 1/2 Clinical Trial of CID-103 in Immune Thrombocytopenia ACCESS Newswire - Mon Jan 6, 2:00AM CST

BEIJING, CHINA / ACCESSWIRE / January 6, 2025 / CASI Pharmaceuticals, Inc. (Nasdaq:CASI), a biopharmaceutical company specializing in the development and commercialization of innovative therapeutic and...

CASI : 2.26 (+1.57%)
Wall Street - Nasdaq Times Square
Nasdaq Futures Fall as Micron’s Sales Outlook Disappoints, U.S. GDP Data and Nike Earnings in Focus Barchart - Thu Jun 27, 2024

September Nasdaq 100 E-Mini futures (NQU24) are trending down -0.23% this morning as an underwhelming sales forecast from chipmaker Micron weighed on sentiment, while investors awaited a flurry of U.S....

NQU24 : 19,808.01s (-0.21%)
MU : 101.32 (-1.74%)
FDX : 245.24 (-0.02%)
AAPL : 213.94 (-0.03%)
WHR : 93.99 (-0.25%)
MRNA : 34.62 (-0.26%)
NKE : 73.97 (+0.37%)
MKC : 81.94 (+0.10%)
WBA : 11.23 (-0.27%)
AYI : 265.57 (-0.62%)
HMB.S.DX : 136.000 (+0.55%)
LEVI : 15.95 (-2.98%)
CASI PHARMACEUTICALS ANNOUNCES SECOND QUARTER 2023 BUSINESS AND FINANCIAL UPDATES PR Newswire - Fri Aug 11, 2023

/PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a biopharmaceutical company focused on developing and commercializing innovative therapeutics and...

CASI : 2.26 (+1.57%)
Mundipharma International Corporation Limited, Mundipharma Medical Company, and Acrotech Biopharma Inc. Enter Agreement to Transfer License of FOLOTYN® (Pralatrexate) in China to CASI Pharmaceuticals PR Newswire - Tue Aug 1, 2023

/PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a biopharmaceutical company focused on developing and commercializing innovative therapeutics and...

CASI : 2.26 (+1.57%)
CASI PHARMACEUTICALS ANNOUNCES FIRST QUARTER 2023 FINANCIAL RESULTS PR Newswire - Wed May 17, 2023

/PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a Cayman Islands incorporated biopharmaceutical company focused on developing and commercializing...

CASI : 2.26 (+1.57%)
CASI Pharmaceuticals Files Annual Report on Form 20-F for Fiscal Year 2022 PR Newswire - Wed Apr 26, 2023

/PRNewswire/ -- CASI Pharmaceuticals, Inc. (NASDAQ: CASI) ("CASI" or the "Company"), a biopharmaceutical company focused on developing and commercializing...

CASI : 2.26 (+1.57%)
CASI PHARMACEUTICALS ANNOUNCES FOURTH QUARTER AND FULL-YEAR 2022 FINANCIAL RESULTS PR Newswire - Wed Apr 26, 2023

/PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a Cayman incorporated biopharmaceutical company focused on developing and commercializing innovative...

CASI : 2.26 (+1.57%)
CASI PHARMACEUTICALS COMPLETES REDOMICILIATION MERGER PR Newswire - Tue Mar 21, 2023

/PRNewswire/ -- CASI Pharmaceuticals, Inc. (NASDAQ: CASI) ("CASI" or the "Company"), a biopharmaceutical company focused on developing and commercializing...

CASI : 2.26 (+1.57%)
CASI PHARMACEUTICALS AND CLEAVE THERAPEUTICS ANNOUNCE CLINICAL TRIAL APPLICATION APPROVAL FOR CB-5339 IN PATIENTS WITH MULTIPLE MYELOMA IN CHINA PR Newswire - Fri Jan 6, 2023

/PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a U.S. biopharmaceutical company focused on developing and commercializing innovative therapeutics...

CASI : 2.26 (+1.57%)
CASI PHARMACEUTICALS' PARTNER JUVENTAS ANNOUNCES NEW DRUG APPLICATION FOR CNCT19 ACCEPTED BY CHINA NATIONAL MEDICAL PRODUCTS ADMINISTRATION PR Newswire - Thu Dec 15, 2022

/PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a U.S. biopharmaceutical company focused on developing and commercializing innovative therapeutics...

CASI : 2.26 (+1.57%)

Barchart Exclusives

Top 10 Stocks to Buy: Xpeng Enters the Top 20. Is It Too Late to Buy? Barchart - 1 hour ago
Chinese EV manufacturer Xpeng moved up six spots in Monday trading to jump into the top 20 of Barchart’s Top 100 Stocks to Buy. Up 150% over the past year, it might be too late to buy. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
Precision Trading with Bollinger Bands: Identifying Breakouts & Reversals
Wed, Mar 26, 2025 5:00 PM UTC
Reserve Your Spot